RNA expression signatures and posttranscriptional regulation in diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages iv35-iv42

  Rudnicki, Michael ^a   Beckers, Anneleen ^b   Neuwirt, Hannes ^a   Vandesompele, Jo ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Biogazelle NV   (Belgium)

Author keywords

chronic renal insufficiency; diabetes mellitus; diabetic kidney disease; diabetic nephropathy; gene expression

Indexed keywords

BIOLOGICAL MARKER; LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; MICRORNA 192; MICRORNA 21; MICRORNA 215; MICRORNA 216A; MICRORNA 25; MICRORNA 29; MICRORNA 93; MICRORNA LET 7; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; DISEASE COURSE; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE TARGETING; GLOMERULUS; HUMAN; KIDNEY INTERSTITIUM; KIDNEY PARENCHYMA; KIDNEY TUBULE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; PROCEDURES; RNA PROCESSING;

BIOMARKERS; DIABETIC NEPHROPATHIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER;

EID: 84939647052     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv079     Document Type: Review

References (82)

1. Mazzucco G, Bertani T, Fortunato M et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002; 39: 713-720
2. Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21: 556-563
3. Hellemons ME, Kerschbaum J, Bakker SJ et al. Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. Diabet Med 2012; 29: 567-577
4. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696
5. Mayer G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 2011; 26: 1132-1137
6. Ju W, Smith S, Kretzler M. Genomic biomarkers for chronic kidney disease. Transl Res 2012; 159: 290-302
7. Yasuda Y, Cohen CD, Henger A, The European Renal cDNA Bank (ERCB) Consortium. Gene expression profiling analysis in nephrology: towards molecular definition of renal disease. Clin Exp Nephrol 2006; 10: 91-98
8. Cohen CD, Gröne H-J, Grone EF et al. Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue. Kidney Int 2002; 61: 125-132
9. Hodgin JB, Borczuk AC, Nasr SH et al. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol 2010; 177: 1674-1686
10. Rudnicki M, Eder S, Perco P et al. Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int 2006; 71: 325-335
11. Rudnicki M, Perco P, Enrich J et al. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest 2009; 89: 337-346
12. Peterson KS, Huang J-F, Zhu J et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004; 113: 1722-1733
13. Baelde HJ, Eikmans M, Doran PP et al. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 2004; 43: 636-650
14. Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55: 2993-3003
15. Lindenmeyer MT, Kretzler M, Boucherot A et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007; 18: 1765-1776
16. Lindenmeyer MT, Rastaldi MP, Ikehata M et al. Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol 2008; 19: 2225-2236
17. Woroniecka KI, Park ASD, Mohtat D et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011; 60: 2354-2369
18. Hodgin JB, Nair V, Zhang H et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013; 62: 299-308
19. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239
20. Tsuchida K, Makita Z, Yamagishi S et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-588
21. Cohen MP, Chen S, Ziyadeh FN et al. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int 2005; 68: 1554-1561
22. Caldwell R, Bartoli M, Behzadian M et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005; 6: 511-524
23. Brosius FC, 3rd, Alpers CE, Bottinger EP et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2503-2512
24. Glinskii AB, Ma J, Ma S et al. Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle 2014; 8: 3925-3942
25. Cabili MN, Trapnell C, Goff L et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25: 1915-1927
26. Taft RJ, Pheasant M, Mattick JS. The relationship between non-proteincoding DNA and eukaryotic complexity. BioEssays 2007; 29: 288-299
27. Liu G, Mattick JS, Taft RJ. A meta-analysis of the genomic and transcriptomic composition of complex life. Cell Cycle 2013; 12: 2061-2072
28. Sauvageau M, Goff LA, Lodato S et al. Multiple knockout mouse models reveal lincRNAs are required for life and brain development. eLife 2013; 2: e01749
29. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Molecular Cell 2011; 43: 904-914
30. Rinn JL, Kertesz M, Wang JK et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-1323
31. Wang KC, Yang YW, Liu B et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011; 472: 120-124
32. Lai F, Orom UA, Cesaroni M et al. Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature 2013; 494: 497-501
33. Tay Y, Zhang J, Thomson AM et al. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008; 455: 1124-1128
34. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5″ UTR as in the 3″ UTR. Proc Natl Acad Sci 2007; 104: 9667-9672
35. Sood P, Krek A, Zavolan M et al. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci USA 2006; 103: 2746-2751
36. Friedman RC, Farh KK-H, Burge CB et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105
37. Jiang Q, Wang Y, Hao Y et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37: D98-D104
38. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014; 20: 460-469
39. Maegdefessel L. The emerging role of microRNAs in cardiovascular disease. J Intern Med 2014; 276: 633-644
40. OConnell RM, Rao DS, Chaudhuri AA et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010; 10: 111-122
41. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-8707
42. Patnaik SK, Kannisto E, Knudsen S et al. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70: 36-45
43. Wang K, Zhang S, Marzolf B et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-4407
44. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838
45. Hall JS, Taylor J, Valentine HR et al. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 2012; 107: 684-694
46. Jung M, Schaefer A, Steiner I et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010; 56: 998-1006
47. Saunders MA, Lim LP. (micro)Genomic medicine: microRNAs as therapeutics and biomarkers. RNA Biol 2009; 6: 324-328
48. Mestdagh P, Hartmann N, Baeriswyl L et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 2014; 11: 809-815
49. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20
50. Krek A, Grün D, Poy MN et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500
51. Lagana A, Forte S, Giudice A et al. miRò: a miRNA knowledge base. Database 2009; 2009: bap008
52. Enright AJ, John B, Gaul U et al. MicroRNA targets in Drosophila. Genome Biol 2003; 5: R1
53. Hsu PWC, Huang H-D, Hsu S-D et al. miRNAMap: genomic maps of microRNA genes and their target genes in mammalian genomes. Nucleic Acids Res 2006; 34: D135-D139
54. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA (New York, N.Y.) 2008; 14: 1012-1017
55. Maragkakis M, Reczko M, Simossis VA et al. DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res 2009; 37: W273-W276
56. Kiriakidou M, Nelson PT, Kouranov A et al. A combined computational-experimental approach predicts human microRNA targets. Genes Dev 2004; 18: 1165-1178
57. Peterson SM, Thompson JA, Ufkin ML et al. Common features of microRNA target prediction tools. Front Genet 2014; 5: 23
58. Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform 2014; 15: 1-19
59. Mestdagh P, Lefever S, Pattyn F et al. The microRNA body map: dissecting microRNA function through integrative genomics. Nucleic Acids Res 2011; 39: e136
60. Moreno-Moya JM, Vilella F, Simón C. MicroRNA: key gene expression regulators. Fertil Steril 2014; 101: 1516-1523
61. Nam S, Kim B, Shin S et al. miRGator: an integrated system for functional annotation of microRNAs. Nucleic Acids Res 2007; 36: D159-D164
62. Cho S, Jun Y, Lee S et al. miRGator v2.0: an integrated system for functional investigation of microRNAs. Nucleic Acids Res 2011; 39: D158-D162
63. Sales G, Coppe A, Bisognin A et al. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Nucleic Acids Res 2010; 38: W352-W359
64. Ulitsky I, Laurent LC, Shamir R. Towards computational prediction of microRNA function and activity. Nucleic Acids Res 2010; 38: e160
65. Kato M, Natarajan R. Diabetic nephropathy - emerging epigenetic mechanisms. Nat Rev Nephrol 2014; 10: 517-530
66. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 2015; 11: 23-33
67. Sun Y, Koo S, White N et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 2004; 32: e188
68. Putta S, Lanting L, Sun G et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 458-469
69. Kato M, Arce L, Wang M et al. A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int 2011; 80: 358-368
70. Krupa A, Jenkins R, Luo DD et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 438-447
71. Wang B, Herman-Edelstein M, Koh P et al. E-cadherin expression is regulated by miR- 192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes. 2010; 59: 1794-1802
72. Deshpande SD, Putta S, Wang M et al. Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 2013; 62: 3151-3162
73. Wang B, Komers R, Carew R et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 2012; 23: 252-265
74. Wang B, Jha JC, Hagiwara S et al. Transforminggrowthfactor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int 2014; 85: 352-361
75. Fiorentino L, Cavalera M, Mavilio M et al. Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. Acta Diabetol 2013; 50: 965-969
76. Basu R, Lee J, Wang Z et al. Loss of TIMP3 selectively exacerbates diabetic nephropathy. Am J Physiol Renal Physiol 2012; 303: F1341-F1352
77. Wang JY, Gao YB, Zhang N et al. miR-21 overexpression enhances TGFβ1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 2014; 392: 163-172
78. Zhong X, Chung AC, Chen HY et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56: 663-674
79. Lai JY, Luo J, O'Connor C et al. MicroRNA-21 in Glomerular Injury. J Am Soc Nephrol 2014
80. Fu Y, Zhang Y, Wang Z et al. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol 2010; 32: 581-589
81. Long J, Wang Y, Wang W et al. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 2010; 285: 23457-23465
82. Argyropoulos C, Wang K, McClarty S et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 2013; 8: e54662